Last Update 24 Mar 26

Fair value Increased 32%

QURE: Evolving FDA Leadership Will Shape Future Gene Therapy Upside

The updated analyst price target for uniQure moves higher to around $38, supported by analysts who see improved regulatory prospects for AMT-130 and the broader pipeline following recent FDA leadership changes, even as views on timelines and trial requirements remain mixed.

Analyst Commentary

Recent research shows a sharp split in how analysts think about uniQure, with some pointing to a more flexible regulatory backdrop as a key upside driver and others staying focused on trial risk, ethics concerns, and competitive pressure in Huntington's disease.

Bullish Takeaways

Bullish analysts highlight the reported departure of key FDA leadership as a potential positive for AMT-130. They argue that it could support a broader discussion around acceptable evidence for rare disease approvals and, in turn, justify higher valuation targets.
Several upgraded views and raised price targets, including moves from low double digits into the US$30 to US$70 range, reflect confidence that AMT-130's existing dataset and the wider gene therapy pipeline can support meaningful long term value if regulators accept alternative trial designs.
Supportive analysts point to strong backing from Huntington's disease communities and media criticism of earlier FDA positions as a potential tailwind for future regulatory dialogue, which they see as material for uniQure's execution risk profile.
Some research notes frame uniQure shares as positioned for a potential "value inflection." Current trading levels are described as close to cash and giving limited credit to AMT-130 or earlier stage programs, which these analysts view as an opportunity if programs progress.

Bearish Takeaways

Bearish analysts focus on the FDA's strong push for a randomized, sham surgery controlled Phase 3 trial for AMT-130, calling it a "worst case regulatory scenario." They argue that it could extend timelines by multiple years and add substantial execution risk.
Several downgrades to Neutral or equivalent, alongside price targets clustered in the US$9 to US$16 range, cite lower confidence that regulators will accept external controls or reverse prior feedback. This weighs on perceived risk reward.
Concerns also center on the ethical and practical challenges of sham brain surgery, with some analysts arguing such a trial may be hard to enroll and could weaken uniQure's position versus less invasive Huntington's disease approaches in Phase 3 development.
In addition to AMT-130 uncertainty, cautious analysts point to mixed progress in other programs, including paused enrollment or dose holds, and argue that these factors justify more conservative expectations for growth and pipeline driven upside.

What's in the News

A senior FDA official reportedly called uniQure's Huntington's gene therapy a failed product and described an earlier study as stone cold negative, noting the agency's expectation for a sham surgery controlled trial for future evaluation (Bloomberg).
Reports highlight that the FDA is pushing uniQure to run a Huntington's disease trial with a sham surgery placebo group, raising ethical and feasibility questions that could affect the path to any potential U.S. approval (Bloomberg).
Coverage of FDA personnel changes notes that Dr. Vinay Prasad, described as having refused a Huntington's drug review from uniQure in the past, is leaving the agency at the end of April, which investors are watching as a possible shift in regulatory tone for several gene therapy companies (New York Times report summary).
Broader reporting on the FDA's accelerated approval process describes a narrower and less predictable path for rare disease drugs, with uniQure mentioned among companies operating in this tighter framework (Wall Street Journal report summary).
A securities fraud class action filed against uniQure in the Southern District of New York alleges investors were misled about the regulatory path and interpretation of AMT-130 trial data, focusing on the use of external controls and expectations around a potential accelerated approval filing (Kessler Topaz Meltzer & Check, LLP announcement).

Valuation Changes

Fair value has risen from $28.67 to $37.84, reflecting a higher assessed central case for uniQure's equity value.
The discount rate has edged lower from 8.14% to 7.70%, indicating a slightly reduced required return in the updated model.
The revenue growth assumption has moved higher from 75.64% to 110.21%, implying a much steeper projected expansion in dollar sales over the forecast period.
The net profit margin has shifted from 10.89% to 14.92%, pointing to a higher expected share of revenue converting into net income in the model.
The future P/E has fallen from 290.01x to 161.01x, indicating a lower valuation multiple being applied to projected earnings despite the higher fair value estimate.

0 views

Key Takeaways

Accelerated approval of AMT-130 for Huntington's could significantly boost future revenues as it would be a pioneering treatment.
Strategic financial actions and strong cash reserves provide resilience and flexibility, supporting pipeline advancement and likely improving margins.
Reliance on AMT-130’s success and regulatory outcomes, amid revenue challenges and manufacturing changes, heightens exposure to product development and supply chain risks.

Catalysts

About uniQure

Develops treatments for patients suffering from rare and other devastating diseases in the United States.What are the underlying business or industry changes driving this perspective?

The potential accelerated approval for AMT-130 in treating Huntington's disease could significantly boost future revenues as it would be one of the first disease-modifying treatments available for this condition.
Expansion of the clinical pipeline with new studies in refractory temporal lobe epilepsy, Fabry disease, and SOD1-ALS could lead to additional revenue streams if these treatments are successful and commercialized.
The company’s strategic financial moves, including reducing cash burn and strengthening the balance sheet through a targeted offering, provide financial resilience and flexibility to support pipeline advancement and potentially improve net margins.
With strong cash reserves of over $400 million, uniQure is well-positioned to fund operations through the launch of AMT-130 and support other key data readouts, likely impacting earnings positively.
Impressive clinical results and newly granted breakthrough therapy designation for AMT-130 might enhance investor confidence, potentially driving stock value through anticipated increases in revenue and investor sentiment.

uniQure Future Earnings and Revenue Growth

Assumptions

How have these above catalysts been quantified?

Analysts are assuming uniQure's revenue will grow by 110.2% annually over the next 3 years.
Analysts are not forecasting that uniQure will become profitable in next 3 years. To represent the Analyst Price Target as a Future PE Valuation we will estimate uniQure's profit margin will increase from -1236.0% to the average US Biotechs industry of 14.9% in 3 years.
If uniQure's profit margin were to converge on the industry average, you could expect earnings to reach $22.3 million (and earnings per share of $0.29) by about March 2029, up from -$199.0 million today. However, there is a considerable amount of disagreement amongst the analysts with the most bullish expecting $84.8 million in earnings, and the most bearish expecting $-298.3 million.
In order for the above numbers to justify the price target of the analysts, the company would need to trade at a PE ratio of 162.3x on those 2029 earnings, up from -5.0x today. This future PE is greater than the current PE for the US Biotechs industry at 16.8x.
Analysts expect the number of shares outstanding to grow by 7.0% per year for the next 3 years.
To value all of this in today's terms, we will use a discount rate of 7.7%, as per the Simply Wall St company report.

Risks

What could happen that would invalidate this narrative?

The company's reliance on successful regulatory outcomes, specifically the BLA submission for AMT-130, coupled with uncertainties about FDA interactions and changes in FDA leadership, poses a risk that could impact revenue and projected market entry timelines.
The decrease in revenue from $8.5 million in Q1 2024 to $1.6 million in Q1 2025 highlights challenges in sustaining revenue streams, which may affect the company's short-term financial health.
The divestiture of the GMP manufacturing facility and reliance on external entities for manufacturing could impact cost efficiencies or lead to potential supply chain disruptions, affecting net margins.
The presence of serious adverse events related to immunosuppression in clinical trials indicates risks that may require additional resources to address or delay product timelines, potentially impacting future earnings.
The company's strong dependency on the success of AMT-130 and limited diversification of revenue-generating products increase their exposure to product development risks which might impact future revenue if any set targets are not met.

Valuation

How have all the factors above been brought together to estimate a fair value?

The analysts have a consensus price target of $37.84 for uniQure based on their expectations of its future earnings growth, profit margins and other risk factors.
However, there is a degree of disagreement amongst analysts, with the most bullish reporting a price target of $94.73, and the most bearish reporting a price target of just $8.91.
In order for you to agree with the analysts, you'd need to believe that by 2029, revenues will be $149.5 million, earnings will come to $22.3 million, and it would be trading on a PE ratio of 162.3x, assuming you use a discount rate of 7.7%.
Given the current share price of $15.92, the analyst price target of $37.84 is 57.9% higher.
We always encourage you to reach your own conclusions though. So sense check these analyst numbers against your own assumptions and expectations based on your understanding of the business and what you believe is probable.

Have other thoughts on uniQure?

Create your own narrative on this stock, and estimate its Fair Value using our Valuator tool.

Create Narrative

How well do narratives help inform your perspective?

Disclaimer

AnalystConsensusTarget is a tool utilizing a Large Language Model (LLM) that ingests data on consensus price targets, forecasted revenue and earnings figures, as well as the transcripts of earnings calls to produce qualitative analysis. The narratives produced by AnalystConsensusTarget are general in nature and are based solely on analyst data and publicly-available material published by the respective companies. These scenarios are not indicative of the company's future performance and are exploratory in nature. Simply Wall St has no position in the company(s) mentioned. Simply Wall St may provide the securities issuer or related entities with website advertising services for a fee, on an arm's length basis. These relationships have no impact on the way we conduct our business, the content we host, or how our content is served to users. The price targets and estimates used are consensus data, and do not constitute a recommendation to buy or sell any stock, and they do not take account of your objectives, or your financial situation. Note that AnalystConsensusTarget's analysis may not factor in the latest price-sensitive company announcements or qualitative material.

QURE: Pivotal Three-Year Huntington’s Data Will Drive Approval and Market Uptake